Oct. 10, 2025, is officially the first-ever National PrEP Day, and MISTR and SISTR are going big. Their goal? Get 10,000 new ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

Earlier this year, we wrote about PrEP (pre-exposure prophylaxis), a drug that prevents people from getting the HIV virus -- but which, after a decade, still needs to make more headway in the gay ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

HIV (human immunodeficiency virus) remains a significant global health challenge, affecting millions of people worldwide. While advancements in medical science have led to better management of the ...

A data analysis found a 22% reduction in HIV pre-exposure prophylaxis (PrEP) prescriptions and a 25% reduction in new PrEP users in the United States after COVID-19 was declared a national emergency.

A little specificity would go a long way in the recommendations of the US Preventive Services Task Force (USPSTF)—that is, if we want health insurance companies to pay for lifesaving HIV prevention ...

Wirth is the CEO of Amida Care. Crowley is the director of the O’Neill Institute’s Center for HIV and Infectious Disease Policy at Georgetown Law. In June, a clinical trial showed that a twice-yearly ...

A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV. PrEP plays a key part in reducing the number of new HIV infections by stopping the virus ...

Increased PrEP usage is linked to decreased HIV diagnosis rates, with a notable decline from 13.0 to 10.6 per 100,000 over a decade. State-level PrEP coverage significantly impacts HIV diagnosis rates ...

A long-acting HIV jab promises near-perfect protection at just $40 a year, but 115 nations must wait for India's approval of ...